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I. Executive Summary 
 
Diabetes is a chronic disease that is characterized by a person having too high blood 
sugar levels due to the deficiency of insulin. If left untreated, there is serious risk for 
development of cardiovascular diseases, renal failure, blindness, nerve damage, etc. Currently, 
this condition is treated by constant monitoring combined with insulin injection. Given that the 
various forms of this treatment have negative effects on overall quality of life, this paper 
focuses on modeling a different type of treatment that can potentially reduce the need for 
constant blood monitoring and reduce the need for insulin supplementation. The treatment 
involves surgically implanting a shunt with β-islet cells next to a blood vessel in the body [1]. 
Here, the β-islet cells release insulin that follows a bell-shaped curve when graphed vs. time [2], 
and this insulin diffuses across a semi-permeable membrane and into the bloodstream. After 
analyzing the results of the model, it was determined that insulin levels with the implant 
matched very closely with natural physiological levels, making this treatment a viable one. This 
treatment also showed the ability to emit a variety of insulin levels making it suitable for a wide 
variety of patients. This makes this a potentially important avenue of research and worthy of 
further study. 
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4 
 
II. Introduction and Design Objectives 
 
2.1. Introduction and Background 
 
Diabetes is a chronic disease that is characterized by a person having too high blood 
sugar levels due to the deficiency of insulin. If left untreated, there is serious risk for 
development of cardiovascular diseases, renal failure, blindness, nerve damage, etc. Currently, 
there is no permanent cure for the disease. In order to restore normal insulin levels, patients 
suffering from diabetes can take daily insulin injections, but this treatment requires one to have 
a very structured lifestyle in order to control blood glucose levels. Another alternative would be 
to use an insulin pump, which can automatically infuse insulin depending on the levels of 
glucose in the blood. This is an improvement over the daily injections, but again the user is 
relegated to participating in less strenuous activities that limit damage to the pump. There is 
also the risk that the pump could stop working, which could cause many inconveniences. Given 
that currently all possible treatments affect one’s normal life greatly, this paper focuses on 
modeling a different type of treatment that potentially has the same positive benefits as an 
insulin pump but is much less invasive in one’s life. That treatment involves surgically 
implanting a shunt with β-islet cells next to a blood vessel in the body [1]. Here, the β-islet cells 
release insulin that follows a bell-shaped curve when graphed vs. time [2], and this insulin 
diffuses across a semi-permeable membrane and into the bloodstream. Axisymmetry is 
assumed, so the membrane and bloodstream are modeled as a slab. Another design was 
considered where a microsphere instead of a shunt was used to store the β-islet cells, but the 
model ended up not being feasible (see Appendix 5.3 for more details). 
 
2.2. Design Objectives 
 
 We will model the insulin production of implanted β-islet cells and its mass transfer 
across a semipermeable membrane. The amount of insulin transferred into the bloodstream 
from this membrane must match normal physiological levels as much as possible. The device 
must also be a minimum length to facilitate implantation into diabetic patients. Satisfying these 
two main constraints is the main objective of the following model. 
 
2.3. Problem Schematic 
 
 Our focus is the modeling in COMSOL of the intravascular arteriovenous shunt, 
implanted with β-islet cells. Schematics of the device are shown in Figure 2.1. A complete 
schematic of our model with all relevant boundary conditions and properties can be found in 
the appendix under mathematical statement of the problem. 
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Fig. 2.1: Schematics of the intravascular arteriovenous shunt. The figure shows the physical shunt as discussed in 
[1]. Our model is shown in Appendix 5.1 
 
III. Results and Discussion 
 
3.1. Insulin Flow Profiles 
 
 As a representative display of insulin concentration profiles in the membrane and in the 
blood, surface plots (see Appendix) were taken at 7200 s, the midpoint of the time window 
being investigated. The flux is at a maximum at this time. There are three plots – one for the 
area where blood enters the implant (Figure 5.5), one for an area further downstream (Figure 
5.6), and one for the area where the blood exits the implant (Figure 5.7). There is very little 
insulin observed in the blood, but that makes sense as the blood is actively carrying the insulin 
away by convection. Note that while the plots are labeled moles per meter cubed, the problem 
was run implicitly replacing meters with millimeters (so the correct units are moles per 
millimeter cubed). 
 Figure 3.1 below is the main focus of the results. It shows the variation of insulin flux out 
of the membrane as a function of time, from 0 to 14400 s. Insulin output from a normal 
pancreas will vary with many different factors such as glucose and insulin content – all of these 
factors vary with time. This means correct insulin output as a function of time is characteristic 
of a normal and healthy pancreas, and as discussed in our design objectives, we want our shunt 
to mimic the pancreas as much as possible. This graph indicates that our shunt achieved the 
desired goal of physiologically significant levels of insulin flux.  
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Fig. 3.1: A plot of insulin flow rate out of the device and into the blood flow versus time. This plot must match 
regular physiological levels for the design to be verified. 
 
3.2. Sensitivity Analysis 
 
 In doing any modeling, the sensitivity of the system to variation in the input parameters 
is always an issue of interest [5]. With this in mind, we set out to conduct a sensitivity analysis 
and find the uncertainty in our predicted insulin flow rates as well as find the range over which 
alterations in the model were possible. 
 We chose to vary three parameters in our sensitivity analysis: the flux function at 
boundary 7, the diffusivity of insulin in the membrane, and the diffusivity of insulin in the blood. 
We chose to change each parameter twice – once to a low value and again to a high value. We 
then graphed the insulin flow rate for all three cases. The dashed line represents the lower 
bound, the solid line represents the original mean value, and the dotted line represents the 
upper bound. 
 The flux function we used was   This 
came from us fitting a Gaussian bell curve to a graph derived in literature [2]. MatLab was used 
to fit this curve, and it gave 95% confidence intervals for the three parameters it fit. We chose 
to vary only the first parameter (the coefficient of the exponential) because the other two (the 
values inside the exponent) control the shape of the curve, which will stay more or less 
constant as that is dictated by the glucose levels in the body. The coefficient, however, controls 
the magnitude of the insulin flux entering the body, and that is more important to examine. So, 
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we changed the coefficient to  the lower bound in the confidence 
interval, and then changed it to  the upper bound. 
 The diffusivity of insulin in the blood we got from a paper [3] that used the Einstein-
Stokes equation we used in BEE 350 – for some reason, most research in this area uses the 
diffusivity of insulin in water as an approximation and this was the closest we could find. This, 
however, means we weren’t given a range of values. We arbitrarily decided to go up and down 
 in our sensitivity analysis. The original value of this diffusivity was 
 
 The diffusivity of insulin in our membrane was from a paper [4] that gave a range of 
values, so we used their limits,  and  The original 
value used was  
 The graphed results of the analysis are shown below (in the same order as presented 
above, from left to right and then down). The insulin flow rate through the membrane and into 
the blood seems to be particularly sensitive to the diffusivity of insulin in the blood. Varying the 
diffusivity in the membrane does not seem to change the flow much (the dotted line in the 
graph is almost invisible as it is almost exactly in line with the solid line), and the system shows 
an intermediate sensitivity to the flux function. 
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Fig. 3.2: Results of the sensitivity analysis. The solid line is the original flow function as shown in Fig. 3.1. The 
dashed line represents the flow when using the lower bound of the parameter; the dotted line is the same for the 
upper bound. The upper left, upper right, and lower graphs are the sensitivity analyses for the flux function, the 
diffusivity of insulin in the blood, and the diffusivity of insulin in the membrane, respectively. 
 
 The results of our analysis are also in line with what we’d expect. Increasing the flux or 
the diffusivity of insulin in the blood increases the total insulin flow into the blood. Increasing 
the diffusivity of insulin in the membrane shifts the curve left, as it takes less time for the 
insulin to enter the blood. 
 Continuing the analysis, we chose to use the flow at t = 7200 s to find the total 
sensitivity of flow to changes in these three input parameters. In doing so, we used Eqn. (1): 
 
     (1) 
 
where  is the insulin flow rate, a is the coefficient of the flux function, DIB is the diffusivity of 
insulin in the blood, and DIM is the diffusivity of insulin in the membrane. In doing this analysis, 
we used only the upper bounds and the lower bounds of the parameters (i.e. we did not use 
the mean values used in the original model, except for the parameters not being varied – so, for 
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instance, as a was being varied, the diffusivities were kept at their mean values). The results are 
tabulated in Figure 3.3. 
 
 
Parameter Value  
a 
  
a 
  
DIB 
 
 
DIB 
 
 
DIM 
 
 
DIM 
 
 
Fig. 3.3: The second part of the sensitivity analysis. The values shown are at the t = 7200 s, when the insulin flux is 
maximal. Parameters not being varied in each test were set to their original mean values in obtaining the displayed 
values. 
 
As was mentioned before,   and 
 Using Eqn. (1) then gives  
 
This value is the most the flow varies (at the peak of insulin flow, t = 7200 s). It is moderately 
high, mostly due to the high variation seen with the diffusivity of insulin in blood. A future step 
may be to pay special attention to that particular parameter. 
 
3.3. Accuracy Check 
 
 As the exact method of providing insulin we have proposed is a relatively cutting-edge 
design, finding adequate peer-reviewed research on this subject is extremely difficult. However, 
diabetes in general is one of the more well-researched conditions in modern society and while 
our exact method may not be as extremely well researched, there are several other methods of 
insulin supply that provide an appropriate analogue. One of these methods is the use of an 
insulin pump. An insulin pump is subcutaneously inserted into the body and then allowed to 
release a pre-determined amount of insulin. This is essentially the same goal as in our project; 
however, our design is actually physically implanted as opposed to merely being attached under 
the skin. The appropriate rate we were trying to achieve is what is known as the body’s basal 
insulin rate. Basal, in this case, refers to a low level of secretion of insulin that is happening 
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continuously throughout the day. While basal insulin rate can vary extraordinarily from person 
to person, an average value would be between 1-2 units of insulin per hour [6].  
 For an appropriate accuracy check of our results, the six insulin flux rates listed above, 
combined with an average flux over the entire time period and the delta value found were 
converted into international units per hour. The tabulated numbers are below. 
 
 
 Insulin Flow Insulin Flow Int. Units 
Peak Values    
    
    
    
    
    
Average Value    
Δ(Flow)    
Fig. 3.4: This is tabulated data showing the insulin flow into the bloodstream in the medical measurement of 
International Units per hour. The conversion factor used is 6.94 nmol = 1 IU. 
 
 This check indicates that our accuracy is quite satisfactory. As an average flow value of 
 yields an effective basal rate of 1.56 IU per hour our model fits directly in the 
middle of the average range of basal rates with a change in flux being able to alter it enough in 
each direction by changing model parameters (the value of  for flow is the 
approximate midpoint of the flux bell curves derived above). This indicates that our experiment 
seems to be appropriate for imitating a basal rate and reduces a diabetic’s need for insulin 
injections. It should also be noted that the peak flux values would significantly decrease the 
need for insulin during meal times. 
 Also it should be noted that it is unnecessary to change these values to a concentration, 
as the basal rate of 1-2 IU per hour is given in terms of mass.  
 
IV. Conclusions and Design Recommendations 
 
4.1. Optimization and Potential of the Device 
 
 With the three conclusions above, of a model that outputs insulin at an accurate 
physiological level and is sensitive to alterations, the device can be optimized for other 
potential patients. 
 From our analysis in the accuracy check, we found that our device as modeled matched 
physiological levels almost perfectly. Due to the sensitivity of the body to insulin levels (as the 
reader can see, the required insulin levels are on the order of picomoles), any small change in 
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the length of the implant will alter the insulin flow enough change the effectiveness of the 
device. To show this, we reduced the length of the implant by one millimeter and plotted the 
resulting insulin flow in Figure 4.1 (the solid line is the original flow graph). The variation at the 
peak is 1.504% - again, this does not seem like much, but even a change of this magnitude can 
affect the functionality of the device. 
 
 
Fig. 4.1: Change in the insulin flow rate due to decreasing the length of the implant by 1 mm. The solid line is the 
original curve, while the dashed line is the curve after the reduction. The value at the peak decreases by 1.504%, 
which can be significant in the context of insulin production. 
 
 Of course, each patient is different, and so the optimal length of the implant will actually 
vary from case to case. As we mentioned, we based our model on a patient of mean 34 yrs and 
mean body mass index of 26.1 [2]. For patients in these ranges, then, a length of 76.2 mm will 
provide near perfect physiological insulin levels. 
 76.2 mm is actually quite long for an implant, however, and a possible way to 
circumvent this is to add more cells by making the cell chamber larger. The constraint in this 
case, however is the nutrient transport into the chamber and to the cells furthest from the 
blood. A similar model to ours, but using oxygen as the species in transport, would illuminate 
this optimization problem easily. 
 The diffusivity of the hydrogel to insulin is the second parameter we can optimize. Since 
our sensitivity analysis showed minimal sensitivity to this parameter, we believe any hydrogel 
with diffusivity around the value used in this model will suffice in terms of perfecting insulin 
flow rates. In worrying about the hydrogel, however, we must turn to a more serious problem, 
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one that plagues tissue engineering in general – the immune response to the implant, which 
usually depends heavily on the nature of the material used. Finding an optimal hydrogel, 
therefore, will require examining the mass transport of immunogenic particles such as IgG. 
Again, our model can be repeated, but using different immunogenic species (such as IgG) to 
accomplish this. 
 In short, our modeling technique for the intravascular arteriovenous shunt can be 
modified with different mass species to obtain an overall picture of the optimal parameters 
required. 
 This shows the flexibility of this model in its potential to improve the quality of life of a 
wide range of people suffering from Type I diabetes.  
 
4.2. Realistic Constraints 
 
 While COMSOL is an incredibly powerful modeling software, it cannot recognize design 
impossibilities that are rooted in the physical reality of a problem. In the case of this implant, 
two of the biggest concerns for this kind of biologically active implant would be the patient’s 
natural immune response and the problem of meeting the implant’s nutrient needs.  
As mentioned above, oxygen flux through the cells and membrane must be found 
because at a certain point the lack of oxygen would cause the implanted cells to die. This would 
be a severe design problem and one that has compounding ramifications when considered with 
other aspects of the implant’s design.  
 Also, the body’s immune response is increased with the body’s increasing exposure to 
the implant. The size of our implant increases the likelihood of an immune reaction and this 
should be negated by reducing the area of our implant. However, this correspondingly would 
make oxygen diffusion through the tissue more difficult. These are realistic constraints which 
require more study in order to ensure that our implant can physically be realized and must be 
of an avenue of careful examination through more modeling or experimentation to ensure that 
the physical reality matches the modeled reality. 
 
4.3. Conclusion 
 
 Diabetes is a condition affecting many Americans that can have life-threatening effects 
at worst or severely impact quality of lift at best. In this case, the primary goal of our model was 
to design something to improve overall patient quality of life by reducing the need for injection 
of insulin. 
 While significant amounts of research remain to be done, the basic feasibility of this 
implant to combat diabetes has been bolstered. With our generated insulin flux values 
matching mean basal rate levels, this implant shows potential to alleviate some of the 
symptoms of diabetes and is worthy of further research.  
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V. Appendix 
 
5.1. Mathematical Statement of the Problem 
 
 We are using axisymmetry (therefore we are modeling a cylinder). In the membrane, 
our governing equation is the mass transfer equation in cylindrical coordinates with no reaction 
and convection: 
 
         (2) 
 
 In the blood, there are two governing equations – the mass transfer equation in 
cylindrical coordinates without reaction and the Navier-Stokes equation. The latter yields a 
velocity profile of this form: 
 
          (3) 
 
 In both the membrane and the blood, there is initially no insulin. 
 
 The boundary conditions used were as follows (Boundary 4 is internal and therefore 
excluded): 
 
Boundary 1 (center axis of blood vessel):  flux is 0 due to symmetry. 
Boundary 2 (entrance of blood vessel):  concentration is 0 because the blood has not  
      picked up any insulin. 
Boundary 3 (exit of blood vessel):   convective flux boundary condition – the flux will  
      be whatever it is at that point. 
Boundary 5, 6 (edges of membrane):  flux is 0 due to membrane attachment to   
      impermeable material. 
Boundary 7 (cell edge of membrane):  flux specified by cells:     
        
 
 The property values used were as follows: 
 
Diffusivity of insulin in membrane:    
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Diffusivity of insulin in blood:     
Volumetric flow rate of blood:    
Velocity profile of blood:     
Length of implant:      
Inner radius of implant:     
Width of membrane:      
Volume of implant:      
Average value of boundary 7 flux function:   
Time window modeled:     
 
 
        Governing Equation: 
         
        Initial Condition:
 
        C = 0 @ time = 0 
        Boundary Conditions: 
        Defined by number above 
        Blood Velocity: 
         
        Properties: 
        Defined above 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2. Technical Details 
 
 The direct (UMFPACK) solver was used to solve the problem. We chose a time step of 
one minute to be as precise as possible without overloading the computer memory. The 
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relative tolerance was 0.01 and absolute tolerance was 0.0010. Relative tolerance is indicative 
of the error relative to the quantity being calculated. For example, percent error is also a kind 
of relative tolerance as the calculated percentage is dependent on both a calculated value and a 
deviation from an accepted value. Absolute tolerance is different as simply the magnitude of a 
number is the only factor of concern. These values listed above were obtained from COMSOL 
and indicate tolerances within calculated output values and were calculated for our main 
variable of interest the blood insulin concentration. 
 
5.3. Mesh Statistics for the Microsphere (fail) 
 
 As was mentioned in the report, we attempted to model a microsphere to compare it 
with the shunt (the main focus of the project). In doing this we modeled a sphere of radius 0.25 
mm. In COMSOL this corresponds to an axisymmetric geometry using a half-circle. Because the 
spheres are not membrane-encapsulated, the boundary of the sphere has the time-dependent 
flux condition  We arrived at this equation 
by using the original insulin flow equation and scaling down by volume. 
 We chose to model 2.25 mm of blood on one side of the sphere (so the sphere is in the 
exact center of the blood vessel) because this is the distance used in the other device. The 
equation for blood flow is the same. All boundaries have zero flux except for the exit, which is 
free. 
 The model described here has major flaws, the first being that such a small sphere will 
not remain stationary in the blood as the model suggests. Also, many such spheres are 
implanted, leading to more complex concentration profiles. Finally, as we found while doing 
mesh convergence, the tiny amounts of insulin involved actually gives the computer problems: 
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Fig. 5.1: Mesh convergence for the microsphere model. As of 11587 elements, the mesh not only does not 
converge, but fluctuates through positive and negative values, implying the computer cannot handle such small 
numbers. 
 
 In the shunt, we got mesh convergence at ~500 elements. Here, we went to 11587 
elements and the concentration is still changing; furthermore, it fluctuates between positive 
and negative values (this is the reason a mesh plot of the microsphere is not included in this 
text). From here we concluded that the microspheres cannot be modeled in COMSOL using the 
approach we used before. Instead, much more complex analyses must be done, and 
considering we only wanted to model this alternative device as a comparison to the main 
cylindrical device, given the time we have remaining in the project we felt continuing in this 
regard was not worth it. 
 
5.4. Mesh Statistics for the Intravascular Arteriovenous Shunt (success) 
 
 Our mesh statistics are as follows (our mesh size is very small compared to our 
geometry, and so a mesh plot would appear uniformly gray even at the most zoomed-in): 
 
Number of degrees of freedom  19669 
Number of mesh points   4995 
Number of elements (total)   4840 
Number of elements (triangular)  0 
Number of elements (quadrilateral)  4840 
Number of boundary elements  418 
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Number of vertex elements   6 
Minimum element quality   0.086 
Element area ratio    0.48 
 
 The parameter used to find mesh convergence was the average concentration of insulin 
in the membrane. This value is almost completely irrelevant in the grand scheme of the project, 
but it provides a single variable from which to find mesh convergence. 
 In finding mesh convergence, the time-dependent boundary condition for flux was not 
used (because the average concentration was found at the last time step anyway). Instead, the 
average value of the flux function was used. The values for mesh convergence are as follows 
(the number of mesh elements only reflects the number of elements in the membrane 
subdomain, because that’s where the integration was taking place): 
 
nelements ninsulin  cav  
20   
80   
320   
440   
660   
720   
Fig. 5.3: Numerical data for mesh convergence. 
 
 It can be concluded, therefore, that 440 mesh elements is sufficient for mesh 
convergence. The results are shown graphically here: 
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Fig. 5.4: Mesh convergence for the shunt. Convergence happened at 440 elements. 
 
5.5. Figures not Included in the Text 
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Fig. 5.5: Surface plot of insulin concentration at the area of the device where blood is exiting. 
 
 
Fig. 5.6: Surface plot of insulin concentration at the middle of the device. 
 
20 
 
 
Fig. 5.7: Surface plot of insulin concentration at the area of the device blood is entering. 
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